Investing.com — Shares in biopharmaceutical firm Ardelyx (NASDAQ:) experienced a significant rally, surging as much as 15% intraday, marking the most substantial increase since May 3.
The rally followed the company’s announcement of preliminary fourth-quarter and full-year revenue for Ibsrela, its treatment for irritable bowel syndrome with constipation.
The revenue figures reported by Ardelyx exceeded the average analyst estimates. The company revealed that its fourth-quarter US net product sales revenue for Ibsrela reached $54 million, surpassing the Bloomberg consensus estimate of $45.4 million.
Looking ahead, Ardelyx anticipates its full-year 2025 US net product sales revenue for Ibsrela to land between $240 million and $250 million.
This projection stands above the estimated figure of $229.6 million. The company’s optimistic outlook for Ibsrela’s sales performance appears to have resonated with investors, as reflected in the stock’s performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
